The U.S. and China asthma and COPD drugs market is positioned for steady expansion, supported by the growing burden of respiratory diseases, improvements in diagnosis, increasing patient awareness, and continued innovation in drug development. Based on the supplied market data, the market was valued at US$13.0 billion in 2015 and was projected to reach US$18.7 billion by 2024, representing a...